Skip to main content

EULAR 2025 - Day 5 podcast

Biologic Switching in PsA Decoding Difficult to Treat PsA Deucravacitinib in Psoriatic Arthritis: A New Oral Option with Dual Impact GLP 1 Receptor Agonists in axSpA Patients Jekyll and Hyde: which RA-ILD is it? RA treatment: A Constant State of Evolution

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×